A Multicenter, Open-label, Randomised, Comparative, Parallel-Arm, Phase II Study to Assess Efficacy and Safety of Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent

Trial Profile

A Multicenter, Open-label, Randomised, Comparative, Parallel-Arm, Phase II Study to Assess Efficacy and Safety of Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs Myrcludex-B (Primary) ; Peginterferon alfa
  • Indications Hepatitis B; Hepatitis D
  • Focus Therapeutic Use
  • Sponsors Hepatera
  • Most Recent Events

    • 30 Aug 2016 Status changed to active, no longer recruiting.
    • 30 May 2016 New trial record
    • 25 May 2016 The company plans to complete the recruitment by the end of 2016 and to have first results in Q3 2018, according to a Hepatera media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top